Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
621-640 of 847 trials

Seizures in Developmental and Epileptic Encephalopathy: Bexicaserin (LP352)

We are studying the safety and effectiveness of a new medication, bexicaserin, for treating seizures in children and adults with developmental and epileptic encephalopathy. This research aims to understand how well it works for managing their condition.

Developmental and Epileptic Encephalopathies1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Mitapivat for Children with Pyruvate Kinase Deficiency

We are studying whether Mitapivat can help increase hemoglobin levels in children with Pyruvate Kinase Deficiency who do not receive regular blood transfusions. This trial compares the treatment to a placebo to assess its effectiveness.

Pyruvate Kinase Deficiency Anemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteHematologyPediatrics

Metoprolol for Heart Health in Duchenne Muscular Dystrophy

We are studying whether metoprolol can help prevent heart issues in boys aged 8-17 with Duchenne Muscular Dystrophy. This trial will compare its effects to a placebo alongside standard heart care.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyNeurology

Cerebral Adrenoleukodystrophy: Leriglitazone Study

We are studying whether leriglitazone can improve survival and slow disease progression in adult males with cerebral adrenoleukodystrophy. Participants will receive either the medication or a placebo to compare effects.

Adrenoleukodystrophy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Advanced Breast Cancer: The p53 Trial

We are testing a chemotherapy treatment for patients with advanced breast cancer that has TP53 mutations. The goal is to see how well it works and to understand the safety and response of different mutation types.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Desmoid Tumors: Nirogacestat Study for Women

We are studying how Nirogacestat affects ovarian function in adult premenopausal women with desmoid tumors. The trial aims to understand any ovarian toxicity and the overall safety of the treatment.

Desmoid Tumors (Aggressive Fibromatosis)1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Ulcerative Colitis: SAR442970 Study

We are investigating how effective different doses of SAR442970 are for adults with moderate to severe ulcerative colitis. The study aims to see if it can help improve symptoms and overall quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterology

Multiple Myeloma: HDP-101 Treatment Study

We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyPediatrics

Epithelioid Malignant Pleural Mesothelioma: Atezolizumab and WT1/DC Vaccine

We are studying the safety and effectiveness of adding a new treatment to standard chemotherapy for patients with epithelioid malignant pleural mesothelioma. This trial aims to see if the combination improves treatment outcomes.

Malignant Pleural Mesothelioma6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

MELAS: Testing Zagociguat

We are studying the investigational drug zagociguat to see if it helps reduce fatigue and improve thinking skills in people with MELAS. The trial also looks at its safety and effects on muscle weakness and memory.

MELAS Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Ongoing Safety Study for Patients in Previous Trials

We are monitoring the safety of a treatment for patients who have participated in earlier studies. This study aims to ensure continued support and care for their health.

Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (NHL)>2 yearsSafety phase (I)Post-Trial Drug AccessHematologyOncology

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology